Considering Tapentadol As A First-Line Analgesic: 14 Questions

References

• Baron R , BinderA , AttalN , CasaleR , DickensonAH , TreedeRD . Neuropathic low back pain in clinical practice . Eur. J. Pain20 ( 6 ), 861 – 873 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Greco MC , NavarraP , TringaliG . The analgesic agent tapentadol inhibits calcitonin gene-related peptide release from isolated rat brainstem via a serotonergic mechanism . Life Sci.145 , 161 – 165 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Chen YJ , ChiangCC , HuangPJ , HuangJ , KarcherK , LiH . Tapentadol immediate-release for acute postbunionectomy pain: a Phase III, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan . Curr. Med. Res. Opin.31 ( 11 ), 2001 – 2009 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Elling C , GalicM , SteigerwaldI . Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy . Lancet Neurol.14 ( 7 ), 684 – 685 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Santos J , AlarcaoJ , FareleiraF , Vaz-CarneiroA , CostaJ . Tapentadol for chronic musculoskeletal pain in adults . Cochrane Database Syst. Rev.5 , CD009923 ( 2015 ).
   Google Scholar
• Tzschentke TM , ChristophT , KogelBY . The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol . CNS drugs28 ( 4 ), 319 – 329 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , ChristophT , SchroderWet al. Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview . Schmerz25 ( 1 ), 19 – 25 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Vadivelu N , TimchenkoA , HuangY , SinatraR . Tapentadol extended-release for treatment of chronic pain: a review . J. Pain Res.4 , 211 – 218 ( 2011 ).
   PubMedGoogle Scholar
• Smith HS , RaffaRB , PergolizziJV , TaylorR , TallaridaRJ . Combining opioid and adrenergic mechanisms for chronic pain . Postgrad. Med.126 ( 4 ), 98 – 114 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Raffa RB , BuschmannH , ChristophTet al. Mechanistic and functional differentiation of tapentadol and tramadol . Expert Opin. Pharmacother.13 ( 10 ), 1437 – 1449 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Monti S , CaporaliR . Chronic pain: the burden of disease and treatment innovations . Reumatismo.67 ( 2 ), 35 – 44 ( 2015 ).
   PubMedGoogle Scholar
• Biondi DM , XiangJ , EtropolskiM , MoskovitzB . Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain . J. Opioid Manag.11 ( 5 ), 393 – 403 ( 2015 ).
   PubMedGoogle Scholar
• Baxter G , MorganCL , Jenkins-JonesS , CurrieCJ , SchultewolterD . Association of adverse events and health service usage with tapentadol prolonged-release treatment compared with morphine controlled-release (cr) and oxycodone cr: a UK primary care observational study . Value Health18 ( 7 ), A658 ( 2015 ).
   Web of Science ®Google Scholar
• Tsutaoka BT , HoRY , FungSM , KearneyTE . Comparative toxicity of tapentadol and tramadol utilizing data reported to the national poison data system . Ann. Pharmacother.49 ( 12 ), 1311 – 1316 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , ChristophT , KogelBet al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties . J. Pharmacol. Exp. Ther.323 ( 1 ), 265 – 276 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Schroder W , TzschentkeTM , TerlindenRet al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia . J. Pharmacol. Exp. Ther.337 ( 1 ), 312 – 320 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cowan A , RaffaRB , TallaridaCSet al. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit . Eur. J. Pain18 ( 8 ), 1148 – 1156 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Stegmann JU , WeberH , SteupA , OkamotoA , UpmalisD , DanielsS . The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery . Curr. Med. Res. Opin.24 ( 11 ), 3185 – 3196 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Afilalo M , EtropolskiMS , KuperwasserBet al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled Phase III study . Clin. Drug Investig.30 ( 8 ), 489 – 505 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Baron R , LikarR , Martin-MolaEet al. Effectiveness of tapentadol prolonged release (pr) compared with oxycodone/naloxone pr for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase IIIb/IV study . Pain Practice16 ( 5 ), 580 – 599 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Biondi D , XiangJ , BensonC , EtropolskiM , MoskovitzB , RauschkolbC . Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain . Pain Physician16 ( 3 ), E237 – E246 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Daniels SE , UpmalisD , OkamotoA , LangeC , HaeusslerJ . A randomized, double-blind, Phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain . Curr. Med. Res. Opin.25 ( 3 ), 765 – 776 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Riemsma R , ForbesC , HarkerJet al. Systematic review of tapentadol in chronic severe pain . Curr. Med. Res. Opin.27 ( 10 ), 1907 – 1930 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Xu XS , EtropolskiM , UpmalisD , OkamotoA , LinR , NandyP . Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR . Pharm. Res.29 ( 9 ), 2555 – 2564 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Terlinden R , OssigJ , FliegertF , LangeC , GohlerK . Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects . Eur. J. Drug Metab. Pharmacokinet.32 ( 3 ), 163 – 169 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• DePriest AZ , PuetBL , HoltAC , RobertsA , ConeEJ . Metabolism and disposition of prescription opioids: a review . Forensic Sci. Rev.27 ( 2 ), 115 – 145 ( 2015 ).
   PubMedGoogle Scholar
• Huntjens DR , LiefaardLC , NandyP , DrenthHJ , VermeulenA . Population pharmacokinetic modeling of tapentadol extended release (ER) in healthy subjects and patients with moderate or severe chronic pain . Clin. Drug Invest.36 ( 3 ), 213 – 223 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lavy E , LeeHK , MabjeeshSJ , SabastianC , BakerY , GiorgiM . Use of the novel atypical opioid tapentadol in goats (Capra hircus): pharmacokinetics after intravenous, and intramuscular administration . J. Vet. Pharmacol. Ther.37 ( 5 ), 518 – 521 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kogel B , TerlindenR , SchneiderJ . Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs . Vet. Anaesth. Analg.41 ( 3 ), 297 – 304 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lee HK , Lebkowska-WieruszewskaB , KimTW , KowaskiCJ , GiorgiM . Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats . Vet. J.198 ( 3 ), 620 – 624 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Zannikos PN , SmitJW , StahlbergHJ , WengeB , HillewaertVM , EtropolskiMS . Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects . J. Opioid Manag.9 ( 4 ), 291 – 300 ( 2013 ).
   PubMedGoogle Scholar
• Gohler K , BrettM , SmitJW , RengelshausenJ , TerlindenR . Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations . Int. J. Clin. Pharmacol. Ther.51 ( 4 ), 338 – 348 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Etropolski MS , OkamotoA , ShapiroDY , RauschkolbC . Dose conversion between tapentadol immediate and extended release for low back pain . Pain physician13 ( 1 ), 61 – 70 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Frampton JE . Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain . Drugs70 ( 13 ), 1719 – 1743 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Iyer SK , MohanG , RamakrishnanS , TheodoreS . Comparison of tapentadol with tramadol for analgesia after cardiac surgery . Ann. Card. Anaesth.18 ( 3 ), 352 – 360 ( 2015 ).
   PubMedGoogle Scholar
• Baron R , JansenJP , BinderAet al. Tolerability, safety, and quality of life with tapentadol prolonged release (pr) compared with oxycodone/naloxone pr in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase IIIb/IV trial . Pain Pract.16 ( 5 ), 600 – 619 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Buynak R , RappaportSA , RodKet al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial . Clin. Ther.37 ( 11 ), 2420 – 2438 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Vadivelu N , KaiA , MaslinB , KodumudiG , LeglerA , BergerJM . Tapentadol extended release in the management of peripheral diabetic neuropathic pain . Ther. Clin. Risk Manag.11 , 95 – 105 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Javed S , AlamU , MalikRA . Burning through the pain: treatments for diabetic neuropathy . Diabetes Obes. Metab.17 ( 12 ), 1115 – 1125 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Javed S , PetropoulosIN , AlamU , MalikRA . Treatment of painful diabetic neuropathy . Ther. Adv. Chronic Dis.6 ( 1 ), 15 – 28 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Schwartz S , EtropolskiM , ShapiroDYet al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial . Curr. Med. Res. Opin.27 ( 1 ), 151 – 162 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mercadante S , PorzioG , FerreraPet al. Tapentadol in cancer pain management: a prospective open-label study . Curr. Med. Res. Opin.28 ( 11 ), 1775 – 1779 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Brunetti GA , PalumboG , MoranoGSet al. Tapentadol PR for pain syndromes in real life patients with hematological malignancy . Cardiovasc. Hematol. Agents Med. Chem.14 ( 1 ), 68 – 74 ( 2016 ).
   PubMedGoogle Scholar
• Wiffen PJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain . Cochrane Database Syst. Rev.25 ( 9 ), CD011460 ( 2015 ).
   Google Scholar
• Pergolizzi JV . Quantifying the impact of drug-drug interactions associated with opioids . Am. J. Manag. Care17 ( Suppl. 11 ), S288 – S292 ( 2011 ).
   PubMedGoogle Scholar
• Pergolizzi JV Jr , LabhsetwarSA , PuenpatomRA , JooS , Ben-JosephR , SummersKH . Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions . Pain Pract.11 ( 4 ), 325 – 336 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr , LabhsetwarSA , PuenpatomRA , JooS , Ben-JosephRH , SummersKH . Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids . 11 ( 3 ), 230 – 239 ( 2011 ).
   Google Scholar
• Pergolizzi JV Jr , MaL , FosterDRet al. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients . J. Manag. Care Pharm.20 ( 5 ), 467 – 476 ( 2014 ).
   Web of Science ®Google Scholar
• Samer CF , LorenziniKI , RollasonV , DaaliY , DesmeulesJA . Applications of CYP450 testing in the clinical setting . Mol. Diagn. Ther.17 ( 3 ), 165 – 184 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Snidvongs S , MehtaV . Recent advances in opioid prescription for chronic non-cancer pain . Postgrad. Med. J.88 ( 1036 ), 66 – 72 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Coluzzi F , RuggeriM . Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain . Curr. Med. Res. Opin.30 ( 6 ), 1139 – 1151 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration Department of Justice . Schedules of controlled substances: placement of tapentadol into schedule II. Final rule . Fed. Reg.74 ( 97 ), 23790 – 23793 ( 2009 ).
   PubMedGoogle Scholar
• Dart RC , SurrattHL , Le LaitMCet al. Diversion and illicit sale of extended release tapentadol in the United States . Pain Med.17 ( 8 ), 1490 – 1496 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Butler SF , McNaughtonEC , BlackRA . Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment . Pain Med.16 ( 1 ), 119 – 130 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Cepeda MS , FifeD , KihmMA , MastrogiovanniG , YuanY . Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse . Clin. J. Pain.30 ( 12 ), 1051 – 1056 ( 2013 ).
   Web of Science ®Google Scholar
• Taylor N . Chronic low back pain: reimbursement and uptake of novel agents and tamper-resistant opioids among payers and prescribers (2012).https://decisionresourcesgroup.com/report/952/
   Google Scholar
• Comfort C . The majority of surveyed PCPs and pain specialists indicate that they have experienced reimbursement restrictions when prescribing Janssen’s Nucynta ER for chronic low back pain . Business Wire ( 2012 ). http://www.businesswire.com/news/home/20120827005702/en/Majority-Surveyed-PCPs-Pain-Specialists-Experienced-Reimbursement .
   Google Scholar